R-Spondin 2/3 BMP Signaling Inhibition for Leukemia Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for leukemia, particularly acute myeloid leukemia (AML), are inadequate in addressing the uncontrolled proliferation and impaired differentiation of myeloid precursors, and there is a need for targeted therapies that can inhibit bone morphogenetic protein (BMP) receptor signaling to prevent or treat leukemia.

Innovation Solution

Inhibitors of R-spondin 2 and/or R-spondin 3-mediated BMP receptor signaling are developed to target and reduce BMP receptor activity, using immunoglobulins, RNAi agents, or other specific compounds to prevent BMP receptor inhibition, thereby modulating WNT signaling pathways.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If R-spondin 2 and/or R-spondin 3 are used to inhibit BMP receptor signaling, then leukemia cell proliferation is reduced and differentiation is improved, but the complexity of the treatment mechanism increases due to involvement of multiple signaling pathways (WNT and BMP)

Engineering Contradiction:

Improveeffectiveness of leukemia treatmentVSAvoidcomplexity of treatment mechanism

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

R-spondin 2 and/or R-spondin 3 act as intermediary molecules that modulate BMP receptor signaling activity. These proteins bind to BMP receptors and prevent inappropriate activation, thereby controlling leukemia cell proliferation and differentiation through a defined molecular mechanism involving the BMP signaling pathway

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If inhibitors of R-spondin 2 and/or R-spondin 3-mediated BMP receptor signaling are developed, then targeted therapy for leukemia is achieved, but the manufacturing complexity and cost increase

Engineering Contradiction:

Improvetargeted therapy capabilityVSAvoidmanufacturing complexity

Core Design Contradiction:

Adaptability or versatilityVSEase of manufacture

Solution Approach 1:

The invention utilizes natural variations in R-spondin 2 and/or R-spondin 3 protein structures and their binding affinities to BMP receptors to develop inhibitors with different specificities and potencies. By modifying parameters such as protein sequence, domain composition, and binding characteristics, targeted therapy agents can be created with optimized therapeutic profiles

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The inhibitors effectively reduce BMP receptor activity, potentially inhibiting leukemia cell growth and differentiation, offering a therapeutic approach to treat and prevent leukemia by targeting key signaling pathways.

Implementation Method 1

R-spondin 2 and/or R-spondin 3 mediated bone morphogenetic protein (BMP) receptor inhibition

Methodology Applied

Scientific EffectProtein-protein binding interaction:

Implementation Method 2

inhibitor of R-spondin 2 and/or R-spondin 3 mediated bone morphogenetic protein (BMP) receptor inhibition

Methodology Applied

Scientific EffectCompetitive binding inhibition:

Data Source

PatentUS20250346890A1Leukemia treatment

Publication Date: 2025.11.13 DEUTES KREBSFORSCHUNGSZENT STIFTUNG DES OFFENTLICHEN RECHTS

AI summary

The present invention relates to an inhibitor of R-spondin 2 and/or R-spondin 3 mediated bone morphogenetic protein (BMP) receptor inhibition for use in treating and/or preventing leukemia in a subject; and to methods, kits, combined preparations, and uses related thereto.